Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.43 | N/A | -11.69% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.43 | N/A | -11.69% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed concerns about current financial performance, particularly in relation to EPS. They reiterated their commitment to long-term goals.
Management highlighted ongoing challenges in achieving profitability.
They emphasized a focus on long-term strategy despite short-term setbacks.
The earnings report indicates that ACADIA PHARMACEUTICA is still struggling with its financial performance, as evidenced by the EPS miss. The stock reacted negatively, dropping 1.51% in response to the disappointing results. Investors may be concerned about the lack of revenue data and guidance, which adds uncertainty to the company's future outlook.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
Nov 2, 2007